The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs
to-BBB and Dr. Olaf van Tellingen from the Department of clinical chemistry of The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI-AVL) will collaborate on the development of a potential new therapy for brain tumors.
Chemotherapeutic treatment options for primary and metastatic brain cancer patients are limited and overall prognoses are dismal. To a large extend this is due to the neuroprotective role of the blood-brain barrier (BBB), limiting the safe delivery of many anti-cancer drugs to their disease target in the brain.
The research group of Dr. van Tellingen has developed a series of advanced experimental models to address key topics in the development of new therapies for Brain Tumors, including their transport across the blood-brain barrier.
to-BBB’s G-Technology™ is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated stealth liposomes. The G-Technology™ has shown proof of concept in several disease models, based on which the research group of Dr. van Tellingen and to-BBB will join forces to develop brain-targeted liposomes with encapsulated anti-cancer drugs.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
